Acurx Pharmaceuticals, Inc.

Stocks

ACXP

US00510M2035

Market Closed - Nasdaq Other stock markets 04:00:00 2026-06-17 pm EDT			5-day change	1st Jan Change
1.540 ^USD	0.00%		-3.75%	-38.15%

Jun. 16	Acurx Pharmaceuticals, Inc. Announces Presentation Of Results From Leiden University Medical Center Public-Private Partnership For Its DNA Pol IIIC Inhibitors At The Leiden Early Drug Discovery & Development Scientific Conference	CI
Jun. 15	Certain Common Stock of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026.	CI

Transcript : Acurx Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 12, 2026

Published on 05/12/2026 at 09:05 am EDT - Modified on 06/12/2026 at 05:12 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Greetings, and welcome to the Acurx Pharmaceuticals First Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, this conference is being

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Acurx Pharmaceuticals, Inc.

Jun. 16	Acurx Pharmaceuticals, Inc. Announces Presentation Of Results From Leiden University Medical Center Public-Private Partnership For Its DNA Pol IIIC Inhibitors At The Leiden Early Drug Discovery & Development Scientific Conference	CI
Jun. 15	Certain Common Stock of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026.	CI
Jun. 15	Certain Warrants of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026.	CI
Jun. 15	Certain Stock Options of Acurx Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 16-JUN-2026.	CI
May. 19	Acurx Pharmaceuticals Highlights FDA's Guidance That Could Accelerate Approval Path for Ibezapolstat	CI
May. 12	Acurx Pharmaceuticals, Inc., Q1 2026 Earnings Call, May 12, 2026
May. 11	Acurx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 04	Acurx Pharmaceuticals, Inc. Presents Scientific Poster on DNA Pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global	CI
Apr. 26	Acurx Pharmaceuticals, Inc., Adiso Therapeutics, Inc., Summit Therapeutics Inc., Finch Therapeutics Group, Inc. and Astrazeneca plc Announces Clostridium Difficile Infections Clinical Trial Updates	CI
Apr. 20	Acurx Pharmaceuticals to discuss first quarter 2026 financial results on May 12, 2026 conference call and provide business update	RE
Apr. 16	Acurx Pharmaceuticals, Inc. announces closing of up to $7.1 million registered direct offering priced at-the-market under Nasdaq rules	RE
Mar. 30	Acurx Pharmaceuticals Inc Grants New Patent for Dna Polymerase Iiic Inhibitors	CI
Mar. 24	Top Premarket Gainers	MT
Mar. 13	Acurx Pharmaceuticals, Inc., Q4 2025 Earnings Call, Mar 13, 2026
Mar. 12	Acurx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI